Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling Analysis
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Given the recognition that disease‐modifying therapies should focus on earlier Parkinson's disease stages, trial enrollment based purely on clinical criteria poses significant challenges. The goal herein was to determine the utility of dopamine transporter neuroimaging as an enrichment biomarker in early motor Parkinson's disease clinical trials. Patient‐level longitudinal data of 672 subjects with early‐stage Parkinson's disease in the Parkinson's Progression Markers Initiative (PPMI) observational study and the Parkinson Research Examination of CEP‐1347 Trial (PRECEPT) clinical trial were utilized in a linear mixed‐effects model analysis. The rate of worsening in the motor scores between subjects with or without a scan without evidence of dopamine transporter deficit was different both statistically and clinically. The average difference in the change from baseline of motor scores at 24 months between biomarker statuses was –3.16 (90% confidence interval [CI] = –0.96 to –5.42) points. Dopamine transporter imaging could identify subjects with a steeper worsening of the motor scores, allowing trial enrichment and 24% reduction of sample size.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A better lemon squeezer? maximum-likelihood regression with beta-distributed dependent variables.
Smithson, M., & Verkuilen, J. (2006) · Psychological Methods · doi:10.1037/1082-989x.11.1.54 · Cited by 1,788
Stephenson, D., Hill, D., Cedarbaum, J. M., Tome, M., Vamvakas, S., Romero, K., Conrado, D. J., Dexter, D. T., Seibyl, J., Jennings, D., et al. (2019) · Journal of Parkinson’s Disease · doi:10.3233/jpd-191648 · Cited by 46
Self-citation
Cited by
Stephenson, D., Hill, D., Cedarbaum, J. M., Tome, M., Vamvakas, S., Romero, K., Conrado, D. J., Dexter, D. T., Seibyl, J., Jennings, D., et al. (2019) · Journal of Parkinson’s Disease · doi:10.3233/jpd-191648 · Cited by 46
Self-citationRoth, S. E., Avigan, M. I., Bourdet, D., Brott, D., Church, R., Dash, A., Keller, D., Sherratt, P., Watkins, P. B., Westcott‐Baker, L., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1571 · Cited by 42
Izmailova, E. S., Maguire, R. P., McCarthy, T. J., Müller, M. L. T. M., Murphy, P., & Stephenson, D. (2023) · Clinical and Translational Science · doi:10.1111/cts.13461 · Cited by 17
Self-citation
Metadata
- Authors
- Conrado, D. J., Nicholas, T., Tsai, K., Macha, S., Sinha, V., Stone, J., Corrigan, B., Bani, M., Muglia, P., Watson, I. A., Kern, V. D., Sheveleva, E., Marek, K., Stephenson, D. T., Romero, K., & on behalf of the Critical Path for Parkinson's (CPP) Parkinson's Disease Modeling and Simulation Working Group
- Venue
- Clinical and Translational Science
- Publisher
- Wiley
- Published
- 2017-07-27
- Volume
- 11
- Issue
- 1
- Pages
- 63-70
- ISSN
- 1752-8054 (ISSN-L)
- 1752-8062
- OpenAlex
- W2741558254
- Cited by
- 49
- References
- 2
- FWCI
- 3.58
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling Analysis. https://app.cochat.ai/papers/10.1111/cts.12492
- The paper
- Conrado, D. J., Nicholas, T., Tsai, K., Macha, S., Sinha, V., Stone, J., Corrigan, B., Bani, M., Muglia, P., Watson, I. A., Kern, V. D., Sheveleva, E., Marek, K., Stephenson, D. T., Romero, K., & on behalf of the Critical Path for Parkinson's (CPP) Parkinson's Disease Modeling and Simulation Working Group. (2018). Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling Analysis. Clinical and Translational Science. https://doi.org/10.1111/cts.12492
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.